- Home
- CUE vs APLT Comparison
CUE vs APLT Comparison
Compare CUE & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- APLT
- Stock Information
- Founded
- CUE 2014
- APLT 2016
- Country
- CUE United States
- APLT United States
- Employees
- CUE N/A
- APLT N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- CUE Health Care
- APLT Health Care
- Exchange
- CUE Nasdaq
- APLT Nasdaq
- Market Cap
- CUE 59.5M
- APLT 69.0M
- IPO Year
- CUE 2018
- APLT 2019
- Fundamental
- Price
- CUE $0.74
- APLT $0.42
- Analyst Decision
- CUE Strong Buy
- APLT Buy
- Analyst Count
- CUE 2
- APLT 6
- Target Price
- CUE $3.00
- APLT $6.10
- AVG Volume (30 Days)
- CUE 116.9K
- APLT 859.9K
- Earning Date
- CUE 08-12-2025
- APLT 11-06-2025
- Dividend Yield
- CUE N/A
- APLT N/A
- EPS Growth
- CUE N/A
- APLT N/A
- EPS
- CUE N/A
- APLT N/A
- Revenue
- CUE $8,286,000.00
- APLT $121,000.00
- Revenue This Year
- CUE N/A
- APLT N/A
- Revenue Next Year
- CUE $10.19
- APLT $5,931.24
- P/E Ratio
- CUE N/A
- APLT N/A
- Revenue Growth
- CUE N/A
- APLT N/A
- 52 Week Low
- CUE $0.45
- APLT $0.30
- 52 Week High
- CUE $1.99
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- CUE 38.09
- APLT 38.92
- Support Level
- CUE $0.77
- APLT $0.43
- Resistance Level
- CUE $0.79
- APLT $0.46
- Average True Range (ATR)
- CUE 0.04
- APLT 0.03
- MACD
- CUE -0.01
- APLT -0.01
- Stochastic Oscillator
- CUE 12.87
- APLT 0.35
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.